Andere Sprachen Sanofi

Aktien

920657

FR0000120578

SAN

Pharmazeutika

Realtime Euronext Paris Andere Börsenplätze 17:17:38 10.03.2026			% 5 Tage	Veränd. 1. Jan.
76.17 ^EUR	+0.47%		-4.65%	-7.94%

09.03.	Globale Pharmakonzerne forcieren US-Präsenz angesichts drohender Zölle	RE
09.03.	Pfizers Ekzem-Medikament erreicht Hauptziel in Phase-2-Studie, Spätphasen-Studie geplant	RE

Andere Sprachen

09.03.	Global drugmakers rush to boost US presence as tariff threat looms
09.03.	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study
08.03.	Brazil’s EMS buys Medley
06.03.	Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million
06.03.	Brazil's EMS purchases Sanofi's Medley
05.03.	Sanofi : Depot AMF CP. D260030A01
05.03.	Sanofi proposera à l'AG la nomination de Christel Heydemann comme administratrice
05.03.	Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante
05.03.	Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
05.03.	Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee
05.03.	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
04.03.	Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel
04.03.	Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
04.03.	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
04.03.	CAC 40 : La Bourse de Paris pourrait se stabiliser à l'ouverture, scrutant la situation au Moyen-Orient
04.03.	Euroapi
04.03.	Sanofi acquiert les droits exclusifs mondiaux d'un anticancéreux auprès de Sino Biopharmaceutical
04.03.	Les valeurs à suivre à Paris et en Europe (actualisé)
04.03.	Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals
04.03.	Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib
04.03.	Sino Biopharm Inks Up to $1.5 Billion Deal With Sanofi for Cancer Treatment
04.03.	Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion
03.03.	Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment
03.03.	Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug
03.03.	Sino Biopharmaceutical discloses exclusive license agreement for rovadicitinib with Sanofi